Eurofins Scientific, a laboratory group listed in Paris and controlled by the Martin family, has bought 233 testing, inspection and certification (TIC) firms since 2015, more than any other buyer in our data. Three quarters of them test food or the environment. Measured on EBITDA (earnings before interest, tax, depreciation and amortization), it pays at or above what other buyers pay for laboratories. By its own figures, the businesses it bought in 2024 were priced at 10.0 times their full-year EBITDA; laboratory deals by other buyers had a median of 9.1 times (19 deals).
Most of the price is paid in cash. Earn-outs, the part paid later and only if the business reaches agreed targets, made up 6% of what Eurofins agreed to pay for its 2025 acquisitions. That later money, like the value of any shares a seller keeps, depends on how the lab does once it is part of Eurofins.
Eurofins Companies and Divisions
Eurofins Scientific SE is registered in Luxembourg. It has been listed on Euronext Paris since 1997 and in the CAC 40, the main index of the Paris stock exchange, since 2021. The Martin family holds its stake through Analytical Bioventures; at the end of June 2026 its 36.5% of the shares carried 69.8% of the votes. Dr. Gilles Martin, the group’s chairman and chief executive, controls that holding company.
In 2025 the group had about $8.2bn of revenue and about 65,700 staff. It has more than 950 laboratories in 59 countries and reports them in four areas. The largest, Life, brought in 42% of 2025 revenue. It tests food and feed, the environment, agricultural products and materials, the trades of most of the labs Eurofins buys. BioPharma tests for drug makers, Diagnostic Services and Products runs clinical laboratories, and Consumer and Technology Products Testing covers consumer product testing and advanced materials.
How Many Companies Eurofins Acquires, and What Size
Eurofins has bought in every year since 2015. Its buying peaked at 40 acquisitions in 2022 and ran at 15 to 20 a year from 2023 to 2025.
Its plan to 2027 is to buy businesses with about $280M of combined revenue each year. Its 2025 bolt-on acquisitions, the smaller businesses it adds to its network, were “all fully funded by operating cash flow”, it said in January 2026. A sale to Eurofins is unlikely to hang on financing.
Where a value was published, most of Eurofins’ purchases were small. A value is public for 18 of them. Ten of those were under $50M, and the median across all 18 was $34.8M. Eurofins publishes prices and announcements only for its larger deals, so the purchases without a published value are likely smaller still.
What Eurofins Buys and Where
If your lab tests food or the environment, you are in the trades Eurofins buys most, which account for 175 of its 233 acquisitions. In food and beverage testing, it made more than a quarter of the acquisitions in our data since 2015 (63 of 220).
| Trade | Acquisitions |
|---|---|
| Food, feed, agriculture, supplements and cosmetics testing | 98 |
| Environmental testing, including hazardous materials, water and occupational hygiene | 77 |
| Pharmaceutical, medical device and other life sciences testing | 25 |
| Electrical, EMC and electronics testing | 13 |
| Materials, metallurgical and other industrial testing | 13 |
| Certification, inspection and multi-service | 7 |
Eurofins is narrowing its buying to what it calls its “core testing for life capabilities”. In July 2026 it agreed to buy Element Materials Technology’s North American life sciences testing labs for $400M, and in the half-year results release that month Gilles Martin called the deal “an illustration of the benefits of focus on few activities”. The purchase closed on 1 October 2026, the day Eurofins also completed the sale of its electrical and electronics testing labs to UL Solutions. Eurofins had already sold its digital testing unit, including its cybersecurity testing firms, in 2022.
If your lab tests electrical or electronic equipment, you are now outside the trades Eurofins is concentrating on. It still buys in consumer product testing.
Eurofins has bought in 42 countries. Most of its acquisitions, 147 of 233, were in Europe, where it is based. The United States is its largest single country, with 34.
What Eurofins Pays: Acquisition Multiples
Buyers price a lab as a multiple of its EBITDA, which is operating profit with depreciation and amortization added back, adjusted for one-off costs and the owner’s own pay. At 10 times, a lab with $2M of EBITDA is valued at $20M. That is its enterprise value (EV), the value of the whole business, from which the owner repays any debt and keeps the rest. A revenue multiple divides the same value by revenue.
Taken together, Eurofins’ purchases are priced at or above the laboratory median on EBITDA. By its own figures, everything it bought in 2024 was priced at 10.0x EBITDA, against a median of 9.1x for other buyers’ laboratory deals in our testing laboratory valuation research. That 2024 figure includes clinical labs, and the larger purchases count for most of it. The median of its six deals with published terms is higher, at 12.8x, and five of them were priced above the median for TIC deals of their size in our TIC valuation research.
| Acquisitions | Measured on | Multiple |
|---|---|---|
| Eurofins, all its 2024 acquisitions, its own figure | EBITDA | 10.0x |
| Eurofins, deals with published terms 2019 to 2024, median of 6 | EBITDA | 12.8x |
| Other buyers’ laboratory deals, median of 19 | EBITDA | 9.1x |
| Eurofins, all its 2022 acquisitions, its own figure | Revenue | 1.6x |
| Eurofins, all its 2023 acquisitions, its own figure | Revenue | 1.3x |
| Eurofins, all its 2024 acquisitions, its own figure | Revenue | 1.5x |
| Other buyers’ laboratory deals, median of 61 | Revenue | 2.3x |
On revenue, Eurofins’ yearly figures sit below the 2.3x median for other buyers’ laboratory deals. In 2024 that came down to margin. That year’s purchases earned a 15% EBITDA margin, so 10x EBITDA came to 1.5x revenue. At the same multiple, a lab earning the group’s own 22% margin would have been priced at about 2.2x revenue. For a profitable lab, the EBITDA multiple is the one to compare.
What Eurofins pays for one lab depends on that lab’s margin, and on the competition for it.
What is your lab worth?
Send us three numbers: revenue, EBITDA and revenue growth rate. Within two working days we show you in confidence how your lab measures up against 1,271 laboratory deals, which buyer groups have acquired labs like yours, and how any offer you hold compares with what they paid where terms are published.
Request your valuation assessment or email the numbers to marcin.majewski@aventis-advisors.com.
How Eurofins Structures a Deal
Eurofins pays mostly in cash. Earn-outs made up 6% of what it agreed to pay for its 2025 acquisitions, and 4% in 2024. The rest was cash, paid in the year of the deal. Its 2025 annual report says the earn-out targets are “in general based on revenue and / or a measure of operating profit”.
Those percentages cover a whole year’s buying, which the largest deals dominate, so one lab’s share can differ. At the end of 2025 Eurofins expected to pay former owners about $62M more, depending on how the businesses they sold perform.
Eurofins usually buys the whole company. In 15 of its 233 TIC deals it bought less, leaving the seller with a minority stake, and its accounts carry put and call options over such stakes. A put option lets the seller require Eurofins to buy the remaining shares later; a call option lets Eurofins require the seller to sell them.
What Happens After Closing
Eurofins describes itself as “a network of empowered entrepreneurs” in which each laboratory is “managed by its own independent entrepreneurial leader” (2025 annual report). A lab it buys is run as a separate business under a leader of its own. What changes is the network around it.
Between 2010 and 2025 Eurofins built what it calls a “hub and spoke” network. Work moves from smaller, less efficient sites into large central labs, the hubs, while local labs, the spokes, keep the testing that has to be done near the customer (2025 annual report). The labs are moving onto the group’s own laboratory software, a rollout it expects to finish in 2027. Its 2025 results presentation, published in January 2026, describes newly bought businesses as “not operating optimally” until they are “restructured or reorganised to the Group’s model”.
It also sells units outside its focus, as it did in 2022 and again in 2026. If part of your price is an earn-out or a stake you keep, what it is worth depends on a lab Eurofins may merge, move onto its systems or restructure.
Eurofins Competitors: Who Else Buys Labs Like Yours
Fourteen groups besides Eurofins have each bought 15 or more firms since 2015 in the food, environmental and life sciences trades it is concentrating on. They include listed groups, private equity platforms and the family-controlled Mérieux NutriSciences.
| Buyer | Owner today | Deals in these trades since 2015 | Of which since 2021 | Of which in North America | Of which in Europe |
|---|---|---|---|---|---|
| Eurofins Scientific | Listed (Paris), controlled by the Martin family | 199 | 101 | 30 | 131 |
| Tentamus Group | Private equity (BC Partners) | 66 | 31 | 11 | 50 |
| SGS | Listed (Zurich) | 49 | 24 | 19 | 21 |
| Alliance Technical Group | Private equity (sale to Blackstone agreed January 2026) | 40 | 33 | 40 | 0 |
| ALS | Listed (Sydney) | 32 | 20 | 4 | 17 |
| Normec | Private equity (Astorg) | 32 | 26 | 4 | 28 |
| Onterris (formerly Montrose Environmental) | Listed (New York) | 31 | 7 | 31 | 0 |
| Pace Analytical | Private equity (Leonard Green, with Aurora) | 28 | 19 | 28 | 0 |
| Mérieux NutriSciences | Family (Institut Mérieux), with minority investors | 25 | 6 | 5 | 10 |
| GBA Group | Private equity (Ardian; sale to Bridgepoint agreed July 2026) | 24 | 14 | 0 | 22 |
| Marlowe | Part of Mitie (listed, London) since August 2025 | 18 | 6 | 0 | 18 |
| Certania | Private equity (Greenpeak, Summit Partners) | 17 | 17 | 0 | 17 |
| QIMA | Founder-led, with TA Associates as investor | 16 | 10 | 2 | 10 |
| Groupe CARSO | Private equity (Archimed) | 15 | 12 | 0 | 15 |
| Bureau Veritas | Listed (Paris) | 15 | 5 | 2 | 4 |
Several buy on one continent only. Alliance Technical Group, Onterris and Pace have bought only in North America, and Certania, CARSO and Marlowe only in Europe. Which of these groups would want your lab depends first on where it is. Among the smaller buyers in these trades is Phenna Group, with 12 deals.
In food testing and in environmental testing, in Europe and in North America alike, at least six groups besides Eurofins have each bought three or more firms since 2015. Whichever of those markets your lab is in, it has several buyers to choose from, each with its own price and terms.
We bring those buyers into one sale. We approach the groups with a real reason to want your lab and ask for offers at the same time, on the same information, so you choose between the best offers, Eurofins’ among them, and get the best price.
Is This a Good Time to Sell to Eurofins?
If you run a food, environmental or pharmaceutical testing lab, you would be selling to a buyer that is buying in your trade now. Eurofins expects its 2026 acquisitions, Element included, to exceed its yearly plan. When it agreed the sale to UL Solutions in April 2026, it named “strategic acquisitions in food, environmental, pharmaceutical, clinical and related testing areas” among the uses of the proceeds.
What Eurofins pays for your lab depends on whether anyone else is bidding. It has bought 233 TIC firms since 2015; you sell your lab once. Answer its approach alone and you sell at the price Eurofins sets for what it calls “reasonably valued bolt-on deals” (results releases, February 2024 and January 2025).
So before you answer, we bring in the other groups that buy labs like yours, and you choose between the best offers. If keeping the lab serves you better, we tell you that too.
Talk to us, in confidence, before you reply to Eurofins or sign a letter of intent, the non-binding offer that sets the price and terms before the detailed checks begin. How we run a sale for a TIC company is set out on our M&A advisory for TIC companies page.
Before you reply to a buyer
Send us three numbers: revenue, EBITDA and revenue growth rate. Within two working days we show you in confidence how your lab measures up against 1,271 laboratory deals, which buyer groups have acquired labs like yours, and how any offer you hold compares with what they paid where terms are published.
About Aventis Advisors
We advise owners on sales with typical enterprise values between $5M and $100M, as partners of the Globalscope network. We also advise serial acquirers, which is how we know the way their offers are built and where they leave room.
Recent transactions:
- Advice to Apave on its acquisitions of ISOCERT and De Duurzame Adviseurs.
- Sale of CKSource, the rich-text editor developer, to PSG via Tiugo Technologies, after a global process that drew several letters of intent.
- Advice to Visma on its acquisition of SaldeoSMART.
“We were impressed with Marcin’s negotiating skills and Aventis’ ability to make things happen.”
Sindre Talleraas Holen, M&A Director, Visma
“Aventis Advisors did the heavy lifting so that our management team could stay focused on our business.”
Wiktor Walc, President, CKSource
Write to us at marcin.majewski@aventis-advisors.com. The first conversation is confidential.
Methodology
The count covers majority acquisitions of TIC firms by Eurofins Scientific or a Eurofins company announced since January 2015. The deals come from our TIC deal database, built from Mergermarket and public sources such as press releases, news reports and annual reports, and we checked them against Eurofins’ releases and annual reports. Each deal counts under the group that made it at the time. Labs Eurofins later sold stay in; one 2015 acquisition made by a business before Eurofins bought it stays out. Clinical diagnostic networks that test patients for doctors and hospitals, and drug development businesses, sit outside TIC and outside the count; a few specialist labs, such as dialysis testing, are classed as life sciences testing and count.
Our TIC valuation pages count each deal under the group that owns the buyer today, so they show 236 to 245 for Eurofins, a little more than the 233 here. The table of competing buyers uses that basis for every row, Eurofins included, and counts only food, environmental, pharmaceutical and life sciences testing deals, which is why Eurofins’ row differs slightly from the counts by trade above.
Our laboratory research covers 1,271 deals since 2015; the medians use the deals among them with a published multiple. The laboratory medians we compare with are other buyers’ deals, without Eurofins’ own; our testing laboratory valuation page, which includes them, shows 10.1x EBITDA (24 deals) and 2.4x revenue (72 deals). The medians for TIC deals of a similar size come from our TIC valuation research, in its four bands: under $50M, $50M to $100M, $100M to $500M, and $500M and over. Enterprise value is equity value plus net debt; deal size is enterprise value where disclosed, otherwise the disclosed deal value.
Eurofins’ yearly multiples are its own. They divide what it paid for all the businesses it bought in a year, clinical diagnostics and asset purchases included, by their full-year revenue and, for 2024, their adjusted EBITDA, as stated in its results releases. The 15% margin is our calculation from the same figures. The cash and earn-out shares come from the business combinations note of its 2025 annual report. Euro figures are converted at $1.13 per euro, the 2025 average.